Exabis Library
Welcome to the e-CCO Library!
DOP046: Genome-wide association study of baseline disease characteristics and response to Ustekinumab in moderate to severe Crohn's disease
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
DOP046: Genome-wide association study of baseline disease characteristics and response to Ustekinumab in moderate to severe Crohn’s Disease
2017
ECCO'17 Barcelona
1
DOP046: Higher serum concentrations of vedolizumab are associated with superior endoscopic outcomes in Crohn’s disease: data from the LOVE-CD trial
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
DOP046: Mid- to long-term stability and associated prognostic factors of adalimumab treatment for 1 189 patients with Crohn’s disease: a multicentre cohort study
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
DOP046: Mid- to Long-term Stability and Associated Prognostic Factors of Adalimumab Treatment for 1189 Patients with Crohn’s Disease: A Multicenter Cohort Study
2016
ECCO'16 DOP
1
DOP047: Early fibrostenosis in Crohn's disease is associated with multiple susceptibility loci on Immunochip analysis
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
DOP047: Early fibrostenosis in Crohn’s Disease is associated with multiple susceptibility loci on Immunochip analysis
2017
ECCO'17 Barcelona
1
DOP047: Infliximab exposure predicts superior endoscopic outcomes in patients with active Crohn’s disease: pharmacokinetic–pharmacodynamic analysis of TAILORIX
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
DOP047: PYRAMID registry: an observational study of adalimumab in Crohn’s disease—results at year 7
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
DOP047: PYRAMID registry: an observational study of adalimumab in Crohn’s disease: results at year 7
2016
ECCO'16 DOP
1
DOP048: Delayed response to golimumab therapy: UC patient characteristics and long-term clinical outcome—post-hoc analyses from the PURSUIT programme
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
DOP048: PROFILE trial: predicting outcomes for Crohn's disease using a molecular biomarker
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
DOP048: PROFILE trial: Predicting outcomes for Crohn’s Disease using a molecular biomarker
2017
ECCO'17 Barcelona
1
DOP048: Vedolizumab levels during induction are associated with long-term clinical and endoscopic remission in patients with Inflammatory Bowel Disease
2018
ECCO'18 Vienna
Tuesday, 8 May 2018, 11:36 AM
1
DOP048: Vedolizumab levels during induction are associated with long-term clinical and endoscopic remission in patients with inflammatory bowel disease
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
DOP049: Combination therapy of cyclosporine and vedolizumab is effective and safe for severe, steroid-resistant Ulcerative Colitis patients: A prospective study
2018
ECCO'18 Vienna
Tuesday, 8 May 2018, 11:36 AM
1
DOP049: Combination therapy of cyclosporine and vedolizumab is effective and safe for severe, steroid-resistant ulcerative colitis patients: A prospective study
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
DOP049: Efficacy and safety of golimumab induction
for moderate-to-severe ulcerative colitis in
the United Kingdom: results from the
GO-COLITIS study
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
DOP049: Efficacy and safety of golimumab induction for moderate to severe ulcerative colitis in the United Kingdom: Results from the GO-COLITIS study
2016
ECCO'16 DOP
1
DOP049: Inflammatory dyskinesis: defects of NF-κB dynamic behaviour as a new potential biomarker for personalized medicine in inflammatory bowel disease
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM